Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. Balar, A., Galsky, M. D., Loriot, Y., Dawson, N., Necchi, A., Srinivas, S., Joseph, R., Vaishampayan, U. N., Sridhar, S. S., Quinn, D. I., Drakaki, A., Duran, I., Rosenberg, J. E., Powles, T., Hoffman-Censits, J. H., Cui, N., Mariathasan, S., Thastrom, A., Abidoye, O. O., Bajorin, D. F. AMER SOC CLINICAL ONCOLOGY. 2016
View details for Web of Science ID 000443264100015